BioE 1115
Alternative Names: BioE-1115Latest Information Update: 04 Sep 2023
At a glance
- Originator BioEnergenix
- Class Small molecules
- Mechanism of Action PAS domain kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Dyslipidaemias; Metabolic syndrome
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Dyslipidaemias in USA (PO)
- 04 Sep 2023 Discontinued - Preclinical for Metabolic syndrome in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (PO)